董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Shmuel Cabilly | 男 | Director | 70 | 未披露 | 537.83 | 2020-03-04 |
| Alla Felder | 女 | Director | 46 | 未披露 | 未持股 | 2020-03-04 |
| Nicolas A. Weinstein | 男 | Director | 38 | 未披露 | 32.01 | 2020-03-04 |
| Giuseppe Cipriano | 男 | Director | 62 | 未披露 | 未持股 | 2020-03-04 |
| Dror Ben Asher | 男 | Chief Executive Officer and Chairman of the Board of Director | 54 | 57.56万美元 | 643.13 | 2020-03-04 |
| Eric Swenden | 男 | Director | 76 | 未披露 | 156.53 | 2020-03-04 |
| Kenneth Reed | 男 | Director | 66 | 未披露 | 672.23 | 2020-03-04 |
| Ofer Tsimchi | 男 | Director | 60 | 未披露 | 28.00 | 2020-03-04 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Micha Ben Chorin | 男 | Chief Financial Officer | 51 | 40.93万美元 | 41.25 | 2020-03-04 |
| June Almenoff | 女 | Chief Scientific Officer | 64 | 未披露 | 未持股 | 2020-03-04 |
| Rick D. Scruggs | 男 | Chief Commercial Officer | 60 | 未披露 | 20.50 | 2020-03-04 |
| Dror Ben Asher | 男 | Chief Executive Officer and Chairman of the Board of Director | 54 | 57.56万美元 | 643.13 | 2020-03-04 |
| Reza Fathi | 男 | Senior Vice President Research and Development | 65 | 26.70万美元 | 162.63 | 2020-03-04 |
| Gilead Raday | 男 | Chief Operating Officer | 45 | 39.87万美元 | 99.80 | 2020-03-04 |
| Adi Frish | 男 | Senior Vice President Business Development and Licensing | 50 | 41.41万美元 | 118.63 | 2020-03-04 |
| Guy Goldberg | 男 | Chief Business Officer | 44 | 41.18万美元 | 95.63 | 2020-03-04 |
董事简历
中英对照 | 中文 | 英文- Shmuel Cabilly
-
Shmuel Cabilly，他曾担任我们的董事会成员（2010年8月26日以来），并任职我们薪酬委员会（2011年5月5日以来）。他是免疫学领域的科学家和发明家。任职the Backman Research Institute（位于希望之城）时，他发起一个重组抗体生产的新突破性技术的开发，并获得专利，也被称为“Cabilly Patent”。他也曾担任Ethrog Biotechnology的联席创始人兼首席科学官，在那里他曾发明了干缓冲技术生产液体凝胶电泳的免费一次性装置，以及冷凝分子分离区域至小胶区域。该技术于2001年出售给Invitrogen公司。他是投资者，也担任一些公司的董事会成员，其中包括BioKine Therapeutics Ltd.、Neuroderm Ltd.、Biologic Design Ltd.、Ornim Inc、Efranat Ltd.他持有the Ben Gurion University of Beer Sheva（位于以色列）的生物学理学硕士学位、the Hebrew University of Jerusalem（位于以色列）的免疫学和微生物学工商管理硕士学位，以及the Hebrew University of Jerusalem（位于以色列）的免疫学和微生物学博士学位。
Shmuel Cabilly has served as a member of our board of directors since August 26 2010 and has served on our compensation committee since May 5 2011. Dr. Cabilly is a scientist and inventor in the field of immunology. In the Backman Research Institute of the City of Hope, Dr. Cabilly initiated the development of a new breakthrough technology for recombinant antibody production, which was patented and known as the “Cabilly Patent.” Dr. Cabilly was also a co-founder and a Chief Scientist of Ethrog Biotechnology, where he invented dry buffer technologies enabling the production of a liquid-free disposable apparatus for gel electrophoresis and a technology that enables the condensation of molecular separation zones to a small gel area. This technology was sold to Invitrogen in 2001. Dr. Cabilly serves as a board member at several companies, including Vidac Pharma Ltd., BioKine Therapeutics Ltd., Neuroderm Ltd., Biologic Design Ltd., and Ornim Inc. Dr. Cabilly holds a B.Sc. in Biology from the Ben Gurion University of Beer Sheva, Israel, an M.Sc. in Immunology and Microbiology from the Hebrew University of Jerusalem, Israel, and a Ph.D. in Immunology and Microbiology from the Hebrew University of Jerusalem, Israel. - Shmuel Cabilly，他曾担任我们的董事会成员（2010年8月26日以来），并任职我们薪酬委员会（2011年5月5日以来）。他是免疫学领域的科学家和发明家。任职the Backman Research Institute（位于希望之城）时，他发起一个重组抗体生产的新突破性技术的开发，并获得专利，也被称为“Cabilly Patent”。他也曾担任Ethrog Biotechnology的联席创始人兼首席科学官，在那里他曾发明了干缓冲技术生产液体凝胶电泳的免费一次性装置，以及冷凝分子分离区域至小胶区域。该技术于2001年出售给Invitrogen公司。他是投资者，也担任一些公司的董事会成员，其中包括BioKine Therapeutics Ltd.、Neuroderm Ltd.、Biologic Design Ltd.、Ornim Inc、Efranat Ltd.他持有the Ben Gurion University of Beer Sheva（位于以色列）的生物学理学硕士学位、the Hebrew University of Jerusalem（位于以色列）的免疫学和微生物学工商管理硕士学位，以及the Hebrew University of Jerusalem（位于以色列）的免疫学和微生物学博士学位。
- Shmuel Cabilly has served as a member of our board of directors since August 26 2010 and has served on our compensation committee since May 5 2011. Dr. Cabilly is a scientist and inventor in the field of immunology. In the Backman Research Institute of the City of Hope, Dr. Cabilly initiated the development of a new breakthrough technology for recombinant antibody production, which was patented and known as the “Cabilly Patent.” Dr. Cabilly was also a co-founder and a Chief Scientist of Ethrog Biotechnology, where he invented dry buffer technologies enabling the production of a liquid-free disposable apparatus for gel electrophoresis and a technology that enables the condensation of molecular separation zones to a small gel area. This technology was sold to Invitrogen in 2001. Dr. Cabilly serves as a board member at several companies, including Vidac Pharma Ltd., BioKine Therapeutics Ltd., Neuroderm Ltd., Biologic Design Ltd., and Ornim Inc. Dr. Cabilly holds a B.Sc. in Biology from the Ben Gurion University of Beer Sheva, Israel, an M.Sc. in Immunology and Microbiology from the Hebrew University of Jerusalem, Israel, and a Ph.D. in Immunology and Microbiology from the Hebrew University of Jerusalem, Israel.
- Alla Felder
-
Alla Felder已经同意加入我们的董事会，于我们的普通股在纳斯达克（NASDAQ）上市之日生效。根据以色列公司法律（Israeli Companies Law），公司打算让她担任外部董事，须在我们的股东会议上批准，这将在本次发行完成的三个月之内举行。她于2014年10月被任命为担任Carmit Candy Industries Ltd.（在TASE上市的公司）的董事。此外，自2010年以来她担任两个科技公司的外部首席财务官，同时也服务于以下纳斯达克（NASDAQ）和/或TASE上市的公司的董事会：Enlight Renewable Energy Ltd. Eurocom group； Crow Technologies 1977 Ltd.； Argaman Industries Ltd.； Zmiha Ltd.和Profit Industries Ltd.。在同时期她也服务于一些私营企业的董事会。自2003年以来她在以色列里雄莱锡安的管理学院学术研究部门（College of Management Academic Studies Division）进行各种会计课程演讲。从1997年到2010年她在PriceWaterhouseCoopers工作，在那里她获得高级经理的职位，带领审计小组（审计几家公司的不同部门）。她获得以色列里雄莱锡安的管理学院学术研究部门（College of Management Academic Studies Division）的工商管理和会计学位，纽约城市大学（City University of New York）的金融科学行政硕士学位。
Alla Felder has served as a director on our board of directors and a chairperson of our audit committee and a member of our compensation committee since May 6 2019. Ms. Felder currently serves as a Director in numerous publicly listed leading Israeli companies across several industries, such as Enlight Renewable Energy Ltd., Ashtrom Properties Ltd., Carmit Industries Ltd. and Argaman Industries Ltd. Ms. Felder also served on the board of Neuroderm Ltd., leading up to its acquisition by Mitsubishi Tanabe Pharma Corporation in 2017. Ms. Felder is a business and financial advisor and currently serves as an external CFO for several technology companies and is also a lecturer in the College of Management Academic Studies Division. From 1997 to 2010 Ms. Felder was with PriceWaterhouseCoopers where she served in her last role as a Senior Manager. - Alla Felder已经同意加入我们的董事会，于我们的普通股在纳斯达克（NASDAQ）上市之日生效。根据以色列公司法律（Israeli Companies Law），公司打算让她担任外部董事，须在我们的股东会议上批准，这将在本次发行完成的三个月之内举行。她于2014年10月被任命为担任Carmit Candy Industries Ltd.（在TASE上市的公司）的董事。此外，自2010年以来她担任两个科技公司的外部首席财务官，同时也服务于以下纳斯达克（NASDAQ）和/或TASE上市的公司的董事会：Enlight Renewable Energy Ltd. Eurocom group； Crow Technologies 1977 Ltd.； Argaman Industries Ltd.； Zmiha Ltd.和Profit Industries Ltd.。在同时期她也服务于一些私营企业的董事会。自2003年以来她在以色列里雄莱锡安的管理学院学术研究部门（College of Management Academic Studies Division）进行各种会计课程演讲。从1997年到2010年她在PriceWaterhouseCoopers工作，在那里她获得高级经理的职位，带领审计小组（审计几家公司的不同部门）。她获得以色列里雄莱锡安的管理学院学术研究部门（College of Management Academic Studies Division）的工商管理和会计学位，纽约城市大学（City University of New York）的金融科学行政硕士学位。
- Alla Felder has served as a director on our board of directors and a chairperson of our audit committee and a member of our compensation committee since May 6 2019. Ms. Felder currently serves as a Director in numerous publicly listed leading Israeli companies across several industries, such as Enlight Renewable Energy Ltd., Ashtrom Properties Ltd., Carmit Industries Ltd. and Argaman Industries Ltd. Ms. Felder also served on the board of Neuroderm Ltd., leading up to its acquisition by Mitsubishi Tanabe Pharma Corporation in 2017. Ms. Felder is a business and financial advisor and currently serves as an external CFO for several technology companies and is also a lecturer in the College of Management Academic Studies Division. From 1997 to 2010 Ms. Felder was with PriceWaterhouseCoopers where she served in her last role as a Senior Manager.
- Nicolas A. Weinstein
-
NicolasA.Weinstein自2017年5月11日起担任董事会成员。韦恩斯坦先生自2017年1月起担任梦百合和房地产投资服务公司Water Bear Investments LLC的董事总经理。2014年至2015年，韦恩斯坦先生担任雅培公司/CFR Pharmaceuticals在智利的国家主管。Weinstein先生于2014年担任CFR Pharmaceuticals的营销与销售副总裁，并于2012年至2013年担任CFR Pharmaceuticals的业务开发副总裁。Weinstein从2008年到2010年担任CFR Pharmaceuticals营销和销售副总裁。Weinstein先生目前领导EMC2Fund Ltd.的梦百合和风险投资，并在Olive Tree Ventures Limited Partnership（Israel）拥有合伙权益。持有Universidad Adolfo Ibanez（智利）的财务学士学位，以及the Kellogg School of Management的工商管理硕士学位（2012年），Weinstein先生已根据我们授予任何投资者的权利被EMC2提名到我们的董事会。在2016年12月的公开募股中，该公司向公司投资了至少1500万美元，以提名一人进入董事会，但要遵守我们向美国证券交易委员会提交的招股说明书中所述的各种条件。
Nicolas A. Weinstein has served as a member of our board of directors since May 11 2017. Mr. Weinstein served as Managing Director of Water Bear Investments LLC, a healthcare and real estate investment services company since January 2017. From 2014 to 2015 Mr. Weinstein served as country head in Chile for Abbott Laboratories / CFR Pharmaceuticals. In 2014 Mr. Weinstein served as VP Marketing & Sales of CFR Pharmaceuticals, and from 2012 to 2013 he served as VP Business Development of CFR Pharmaceuticals. From 2008 to 2010 Mr. Weinstein served as VP Marketing & Sales of CFR Pharmaceuticals. Mr. Weinstein currently leads the healthcare and venture investments of EMC2 Fund Ltd. “EMC2” and its partnership interests in Olive Tree Ventures Limited Partnership (Israel) Mr. Weinstein holds an M.Sc. in Finance from Universidad Adolfo Ibanez (Chile) and an MBA from the Kellogg School of Management -2012 Mr. Weinstein has been nominated to our board of directors by EMC2 pursuant to the right we granted to any investor that invested at least $15 million in the Company in our December 2016 public offering to nominate one person to our board of directors, subject to various conditions described in the prospectus that we filed with the Securities Exchange Commission. - NicolasA.Weinstein自2017年5月11日起担任董事会成员。韦恩斯坦先生自2017年1月起担任梦百合和房地产投资服务公司Water Bear Investments LLC的董事总经理。2014年至2015年，韦恩斯坦先生担任雅培公司/CFR Pharmaceuticals在智利的国家主管。Weinstein先生于2014年担任CFR Pharmaceuticals的营销与销售副总裁，并于2012年至2013年担任CFR Pharmaceuticals的业务开发副总裁。Weinstein从2008年到2010年担任CFR Pharmaceuticals营销和销售副总裁。Weinstein先生目前领导EMC2Fund Ltd.的梦百合和风险投资，并在Olive Tree Ventures Limited Partnership（Israel）拥有合伙权益。持有Universidad Adolfo Ibanez（智利）的财务学士学位，以及the Kellogg School of Management的工商管理硕士学位（2012年），Weinstein先生已根据我们授予任何投资者的权利被EMC2提名到我们的董事会。在2016年12月的公开募股中，该公司向公司投资了至少1500万美元，以提名一人进入董事会，但要遵守我们向美国证券交易委员会提交的招股说明书中所述的各种条件。
- Nicolas A. Weinstein has served as a member of our board of directors since May 11 2017. Mr. Weinstein served as Managing Director of Water Bear Investments LLC, a healthcare and real estate investment services company since January 2017. From 2014 to 2015 Mr. Weinstein served as country head in Chile for Abbott Laboratories / CFR Pharmaceuticals. In 2014 Mr. Weinstein served as VP Marketing & Sales of CFR Pharmaceuticals, and from 2012 to 2013 he served as VP Business Development of CFR Pharmaceuticals. From 2008 to 2010 Mr. Weinstein served as VP Marketing & Sales of CFR Pharmaceuticals. Mr. Weinstein currently leads the healthcare and venture investments of EMC2 Fund Ltd. “EMC2” and its partnership interests in Olive Tree Ventures Limited Partnership (Israel) Mr. Weinstein holds an M.Sc. in Finance from Universidad Adolfo Ibanez (Chile) and an MBA from the Kellogg School of Management -2012 Mr. Weinstein has been nominated to our board of directors by EMC2 pursuant to the right we granted to any investor that invested at least $15 million in the Company in our December 2016 public offering to nominate one person to our board of directors, subject to various conditions described in the prospectus that we filed with the Securities Exchange Commission.
- Giuseppe Cipriano
-
Giuseppe Cipriano自2019年11月18日起担任董事会成员。Cipriano先生自2001年以来担任COSMO SPA的首席运营官，并担任多个COSMO实体的执行董事会成员。Cipriano先生在管理制药行业的运营方面拥有丰富的经验，包括人员，制造以及与药品供应商和被许可人的关系。Cipriano先生拥有意大利米兰Manzoni Institute古典语言学士学位。
Giuseppe Cipriano has served as a member of our board of directors since November 18 2019. Mr. Cipriano has served as the Chief Operating Officer of Cosmo SpA since 2001 and as an executive board member of several Cosmo entities. Mr. Cipriano has significant experience in managing operations in the pharmaceutical industry, including personnel, manufacturing, and relations with drug suppliers and licensees. Mr. Cipriano holds a B.A. in Classic Languages from Manzoni Institute in Milan, Italy. - Giuseppe Cipriano自2019年11月18日起担任董事会成员。Cipriano先生自2001年以来担任COSMO SPA的首席运营官，并担任多个COSMO实体的执行董事会成员。Cipriano先生在管理制药行业的运营方面拥有丰富的经验，包括人员，制造以及与药品供应商和被许可人的关系。Cipriano先生拥有意大利米兰Manzoni Institute古典语言学士学位。
- Giuseppe Cipriano has served as a member of our board of directors since November 18 2019. Mr. Cipriano has served as the Chief Operating Officer of Cosmo SpA since 2001 and as an executive board member of several Cosmo entities. Mr. Cipriano has significant experience in managing operations in the pharmaceutical industry, including personnel, manufacturing, and relations with drug suppliers and licensees. Mr. Cipriano holds a B.A. in Classic Languages from Manzoni Institute in Milan, Italy.
- Dror Ben Asher
-
Dror Ben Asher，2009年8月3日起，他担任我公司首席执行官和董事；2011年5月4日起，担任我公司董事会主席；2002年1月至2010年11月，担任P.C.M.I. Ltd.的经理，该公司是ProSeed Capital Holdings CVA的附属机构，为我公司提供咨询服务。他目前担任Agrea Ltd.的董事。他在英国莱斯特大学（University of Leicester）获得法学学士学位，在英国牛津大学（Oxford University）获得法学硕士学位，并在美国哈佛大学（Harvard University）完成了法学硕士学习。
Dror Ben Asher has served as our Chief Executive Officer and as a director since August 3 2009. Since May 4 2011 Mr. Ben-Asher has also served as Chairman of our board of directors. From January 2002 to November 2010 Mr. Ben-Asher served as a manager at P.C.M.I. Ltd., an affiliate of ProSeed Capital Holdings CVA. Mr. Ben-Asher holds an LLB from the University of Leicester, U.K., an MJur. from Oxford University, U.K. and completed LLM studies at Harvard University. - Dror Ben Asher，2009年8月3日起，他担任我公司首席执行官和董事；2011年5月4日起，担任我公司董事会主席；2002年1月至2010年11月，担任P.C.M.I. Ltd.的经理，该公司是ProSeed Capital Holdings CVA的附属机构，为我公司提供咨询服务。他目前担任Agrea Ltd.的董事。他在英国莱斯特大学（University of Leicester）获得法学学士学位，在英国牛津大学（Oxford University）获得法学硕士学位，并在美国哈佛大学（Harvard University）完成了法学硕士学习。
- Dror Ben Asher has served as our Chief Executive Officer and as a director since August 3 2009. Since May 4 2011 Mr. Ben-Asher has also served as Chairman of our board of directors. From January 2002 to November 2010 Mr. Ben-Asher served as a manager at P.C.M.I. Ltd., an affiliate of ProSeed Capital Holdings CVA. Mr. Ben-Asher holds an LLB from the University of Leicester, U.K., an MJur. from Oxford University, U.K. and completed LLM studies at Harvard University.
- Eric Swenden
-
Eric Swenden， 2010年5月3日起，他担任我公司董事会成员，2011年5月5日起担任投资委员会成员；1966年至2001年，他在Vandemoortele Food Group担任多职，包括1985年起担任首席执行官，1990年起担任执行主席，该公司是位于比利时的私营欧洲食品集团，收入大约为20亿欧元。他目前担任Lifeline Scientific, Inc., TBC S.A., Alterpharma N.V。和Gudrun N.V。的董事会成员。他在比利时University of Antwerp获得商学硕士学位。
Eric Swenden has served as a member of our board of directors since May 3 2010 and has served on our investment committee since May 5 2011. From 1966 until 2001 Mr. Swenden served in various positions including Chief Executive Officer since 1985 and Executive Chairman (since 1990) of Vandemoortele Food Group, a privately held Belgium-based European food group with revenue of approximately EUR 2 billion, and he currently serves on the board of directors of TBC S.A. and Maya Gold & Silver Ltd. Mr. Swenden holds an M.A. in Commercial Science from the University of Antwerp, Belgium. The board of directors has determined that Mr. Swenden is a financial and accounting expert under Israeli law. - Eric Swenden， 2010年5月3日起，他担任我公司董事会成员，2011年5月5日起担任投资委员会成员；1966年至2001年，他在Vandemoortele Food Group担任多职，包括1985年起担任首席执行官，1990年起担任执行主席，该公司是位于比利时的私营欧洲食品集团，收入大约为20亿欧元。他目前担任Lifeline Scientific, Inc., TBC S.A., Alterpharma N.V。和Gudrun N.V。的董事会成员。他在比利时University of Antwerp获得商学硕士学位。
- Eric Swenden has served as a member of our board of directors since May 3 2010 and has served on our investment committee since May 5 2011. From 1966 until 2001 Mr. Swenden served in various positions including Chief Executive Officer since 1985 and Executive Chairman (since 1990) of Vandemoortele Food Group, a privately held Belgium-based European food group with revenue of approximately EUR 2 billion, and he currently serves on the board of directors of TBC S.A. and Maya Gold & Silver Ltd. Mr. Swenden holds an M.A. in Commercial Science from the University of Antwerp, Belgium. The board of directors has determined that Mr. Swenden is a financial and accounting expert under Israeli law.
- Kenneth Reed
-
Kenneth Reed， 2009年12月15日起，他担任我公司董事会成员。他是皮肤科医生，在Kenneth Reed MD PC的名下进行个人实践。他目前担任Minerva Biotechnologies Corporation的董事会成员。他在布朗大学（Brown University）获得学士学位，在新泽西医科与牙科大学（University of Medicine and Dentistry of New Jersey）获得医学博士学位。
Kenneth Reed has served as a member of our board of directors since December 15 2009. Dr. Reed is a dermatologist practicing in private practice under the name of Kenneth Reed M.D. PC. Dr. Reed currently serves on the board of directors of Minerva Biotechnologies Corporation. Dr. Reed received his B.A from Brown University in the U.S. and an M.D from the University of Medicine and Dentistry of New Jersey in the U.S. Dr. Reed is a board-certified dermatologist with the over 25 years of clinical experience since completing the Harvard Medical School Residency Program in Dermatology. Dr. Reed is also a co-founder of Early Cell, a prenatal diagnostics company, and Prescient Pharma. - Kenneth Reed， 2009年12月15日起，他担任我公司董事会成员。他是皮肤科医生，在Kenneth Reed MD PC的名下进行个人实践。他目前担任Minerva Biotechnologies Corporation的董事会成员。他在布朗大学（Brown University）获得学士学位，在新泽西医科与牙科大学（University of Medicine and Dentistry of New Jersey）获得医学博士学位。
- Kenneth Reed has served as a member of our board of directors since December 15 2009. Dr. Reed is a dermatologist practicing in private practice under the name of Kenneth Reed M.D. PC. Dr. Reed currently serves on the board of directors of Minerva Biotechnologies Corporation. Dr. Reed received his B.A from Brown University in the U.S. and an M.D from the University of Medicine and Dentistry of New Jersey in the U.S. Dr. Reed is a board-certified dermatologist with the over 25 years of clinical experience since completing the Harvard Medical School Residency Program in Dermatology. Dr. Reed is also a co-founder of Early Cell, a prenatal diagnostics company, and Prescient Pharma.
- Ofer Tsimchi
-
Ofer Tsimchi， 2011年5月4日起，他担任我公司董事外部董事，2011年5月5日起，担任审计委员会成员和薪酬委员会主席；2008年起，担任Polysack Plastic Industries Ltd.和Polysack-Agriculture Products的董事会主席， 2006年起，担任控股公司Danbar Group Ltd.的合伙人。他目前担任Polysack Plastic Industries Ltd, Kidron Industrial Materials Ltd., Amutat Zionut 2000 Danbar Group Ltd，和Polysack Agriculture Hi-Technologies的董事会成员。他在以色列耶路撒冷希伯来大学（Hebrew University of Jerusalem）获得经济学和农业学士学位。
Ofer Tsimchi has served as our director since December 2014. He is a managing partner of Danbar Group Ltd., a management services firm, which he co-founded in 2006. Mr. Tsimchi served as the Executive Chairman of the Board of Polysack Plastic Industries Ltd., which develops and manufactures film products for high-shrink labels, candy wrappers and agro-textiles, from 2008 to 2011. Mr. Tsimchi has been a director of Redhill Biopharma NASDAQ: RDHL, a specialty biopharmaceutical company focused on gastrointestinal diseases, since 2011 Maabarot Products Ltd., Israel’s leading developer, manufacturer, and marketer of a wide range of advanced nutrition and health products for people and pets, since 2014 and Kidron Industrial Materials Ltd., a manufacturer of chemical preparations, since 2003. From 2003 until 2005 he served as director and Chief Executive Officer of Kidron Industrial Holdings Ltd. Group, a manufacturer of precision molded plastic products and components. From 2002 until 2003 Mr. Tsimchi was a Business Development Manager of ProSeed Capital Fund, a venture capital firm. From 2000 until 2001 Mr. Tsimchi acted as the Chief Executive Officer of Insider Financial Services Ltd. From 1997 until 2000 Mr. Tsimchi served as the Chief Executive Officer of Inbar Moulded Fiberglass and from 1993 until 1997 as its Vice President of Marketing and Sales. He was the Community Director and Secretary of Kibbutz Hamadia from 1990 until 1993. Mr. Tsimchi holds a B.Sc. in Economics and Agriculture from the Hebrew University, Israel. - Ofer Tsimchi， 2011年5月4日起，他担任我公司董事外部董事，2011年5月5日起，担任审计委员会成员和薪酬委员会主席；2008年起，担任Polysack Plastic Industries Ltd.和Polysack-Agriculture Products的董事会主席， 2006年起，担任控股公司Danbar Group Ltd.的合伙人。他目前担任Polysack Plastic Industries Ltd, Kidron Industrial Materials Ltd., Amutat Zionut 2000 Danbar Group Ltd，和Polysack Agriculture Hi-Technologies的董事会成员。他在以色列耶路撒冷希伯来大学（Hebrew University of Jerusalem）获得经济学和农业学士学位。
- Ofer Tsimchi has served as our director since December 2014. He is a managing partner of Danbar Group Ltd., a management services firm, which he co-founded in 2006. Mr. Tsimchi served as the Executive Chairman of the Board of Polysack Plastic Industries Ltd., which develops and manufactures film products for high-shrink labels, candy wrappers and agro-textiles, from 2008 to 2011. Mr. Tsimchi has been a director of Redhill Biopharma NASDAQ: RDHL, a specialty biopharmaceutical company focused on gastrointestinal diseases, since 2011 Maabarot Products Ltd., Israel’s leading developer, manufacturer, and marketer of a wide range of advanced nutrition and health products for people and pets, since 2014 and Kidron Industrial Materials Ltd., a manufacturer of chemical preparations, since 2003. From 2003 until 2005 he served as director and Chief Executive Officer of Kidron Industrial Holdings Ltd. Group, a manufacturer of precision molded plastic products and components. From 2002 until 2003 Mr. Tsimchi was a Business Development Manager of ProSeed Capital Fund, a venture capital firm. From 2000 until 2001 Mr. Tsimchi acted as the Chief Executive Officer of Insider Financial Services Ltd. From 1997 until 2000 Mr. Tsimchi served as the Chief Executive Officer of Inbar Moulded Fiberglass and from 1993 until 1997 as its Vice President of Marketing and Sales. He was the Community Director and Secretary of Kibbutz Hamadia from 1990 until 1993. Mr. Tsimchi holds a B.Sc. in Economics and Agriculture from the Hebrew University, Israel.
高管简历
中英对照 | 中文 | 英文- Micha Ben Chorin
Micha Ben Chorin自2016年以来一直担任我们的首席财务官。2014年至2016年，Ben Chorin先生担任商业智能BI软件公司Pyramid Analytics的首席财务官。从2009年到2013年，他担任StarHome B.V.（一家领先的国际漫游供应商）的首席财务官，从2005年到2009年担任无线运营商Winetworks的首席财务官，从1998年到2005年，Ben Chorin先生担任GVT（目前为保罗迪圣电讯）的首席财务官。Ben Chorin先生拥有特拉维夫大学（Tel-Aviv University）的学士学位，是一名注册会计师。
Micha Ben Chorin has served as our Chief Financial Officer since 2016. From 2014 until 2016 Mr. Ben Chorin served as Chief Financial Officer of Pyramid Analytics a business intelligence BI software company. From 2009 until 2013 he served as CFO of Starhome B.V., a leading international roaming vendor, from 2005 until 2009 as CFO of Winetworks, a wireless operator, and from 1998 until 2005 Mr. Ben Chorin served as Chief Financial Officer at GVT (currently Telefonica Brazil). Mr. Ben Chorin holds a B.A. from Tel-Aviv University and is a Certified Public Accountant.- Micha Ben Chorin自2016年以来一直担任我们的首席财务官。2014年至2016年，Ben Chorin先生担任商业智能BI软件公司Pyramid Analytics的首席财务官。从2009年到2013年，他担任StarHome B.V.（一家领先的国际漫游供应商）的首席财务官，从2005年到2009年担任无线运营商Winetworks的首席财务官，从1998年到2005年，Ben Chorin先生担任GVT（目前为保罗迪圣电讯）的首席财务官。Ben Chorin先生拥有特拉维夫大学（Tel-Aviv University）的学士学位，是一名注册会计师。
- Micha Ben Chorin has served as our Chief Financial Officer since 2016. From 2014 until 2016 Mr. Ben Chorin served as Chief Financial Officer of Pyramid Analytics a business intelligence BI software company. From 2009 until 2013 he served as CFO of Starhome B.V., a leading international roaming vendor, from 2005 until 2009 as CFO of Winetworks, a wireless operator, and from 1998 until 2005 Mr. Ben Chorin served as Chief Financial Officer at GVT (currently Telefonica Brazil). Mr. Ben Chorin holds a B.A. from Tel-Aviv University and is a Certified Public Accountant.
- June Almenoff
June Almenoff自2019年5月15日起担任我们的首席科学官。Almenoff博士在制药行业拥有20多年的经验，曾担任多个高级执行职位，包括被Actavis plc收购的Furiex Pharmaceuticals的总裁兼首席医疗官，Actavis plc现为Allergan plc，其主导产品Viberzi®；，于2015年被FDA批准用于治疗肠易激综合征合并腹泻（IBS-D）。在加入Furiex之前，Almenoff博士曾在GlaxoSmithKline plc工作，在那里她担任多个职责递增的职位。她最近担任众多生物制药公司的董事会成员和顾问。她目前是Harrington Discovery Institute和Brainstorm Cell Therapeutics（NASDAQ:BCLI）的Harrington投资顾问委员会的董事会成员。Almenoff博士拥有史密斯学院（Smith College）的B.A.（优等生），并毕业于西奈山医学院（Mt.Sinai School of Medicine）的医学博士-博士项目。她在斯坦福大学医学中心（Stanford University Medical Center）完成内科住院医师和传染病奖学金培训，并任职于杜克大学医学院（Duke University School of Medicine）的教员，在那里她目前担任兼职。
June Almenoff, has served as a director since February 2021. Dr. Almenoff is an accomplished biopharma executive with over 20 years of senior leadership experience. She served as President and Chief Medical Officer of Furiex Pharmaceuticals “Furiex”, which was acquired by Actavis plc now AbbVie for $1.2B. Furiex developed eluxadoline Viberzi®, which is approved in both the United States and Europe. Prior to joining Furiex, Dr. Almenoff was at GlaxoSmithKline (GSK) for 12 years, where she held various positions of increasing responsibility. She was a Vice President in the Clinical Safety Organization, chaired a PhRMA-FDA working group, and worked in the area of scientific licensing. Dr. Almenoff also led the development of pioneering systems for minimizing risk in drug development, which have been widely adopted by industry and regulators. Dr. Almenoff led or contributed to numerous regulatory submissions and product approvals. She is currently Chief Medical Officer of RedHill Biopharma (Nasdaq: RDHL). She also serves on the investment advisory board of the Harrington Discovery Institute and the boards of Brainstorm Cell Therapeutics (Nasdaq: BCLI) and inSoma Bio. Dr. Almenoff has strong expertise in translational medicine, clinical development, commercial strategy, and business development, and has previously advised biotech boards and management in these areas. Dr. Almenoff received her B.A. cum laude from Smith College and graduated with AOA honors from the M.D.-Ph.D. program at the Icahn (Mt. Sinai) School of Medicine. She completed post-graduate medical training at Stanford University Medical Center and served on the faculty of Duke University School of Medicine. She is an adjunct professor at Duke, a Fellow of the American College of Physicians (FACP) and has authored close to 60 publications.- June Almenoff自2019年5月15日起担任我们的首席科学官。Almenoff博士在制药行业拥有20多年的经验，曾担任多个高级执行职位，包括被Actavis plc收购的Furiex Pharmaceuticals的总裁兼首席医疗官，Actavis plc现为Allergan plc，其主导产品Viberzi®；，于2015年被FDA批准用于治疗肠易激综合征合并腹泻（IBS-D）。在加入Furiex之前，Almenoff博士曾在GlaxoSmithKline plc工作，在那里她担任多个职责递增的职位。她最近担任众多生物制药公司的董事会成员和顾问。她目前是Harrington Discovery Institute和Brainstorm Cell Therapeutics（NASDAQ:BCLI）的Harrington投资顾问委员会的董事会成员。Almenoff博士拥有史密斯学院（Smith College）的B.A.（优等生），并毕业于西奈山医学院（Mt.Sinai School of Medicine）的医学博士-博士项目。她在斯坦福大学医学中心（Stanford University Medical Center）完成内科住院医师和传染病奖学金培训，并任职于杜克大学医学院（Duke University School of Medicine）的教员，在那里她目前担任兼职。
- June Almenoff, has served as a director since February 2021. Dr. Almenoff is an accomplished biopharma executive with over 20 years of senior leadership experience. She served as President and Chief Medical Officer of Furiex Pharmaceuticals “Furiex”, which was acquired by Actavis plc now AbbVie for $1.2B. Furiex developed eluxadoline Viberzi®, which is approved in both the United States and Europe. Prior to joining Furiex, Dr. Almenoff was at GlaxoSmithKline (GSK) for 12 years, where she held various positions of increasing responsibility. She was a Vice President in the Clinical Safety Organization, chaired a PhRMA-FDA working group, and worked in the area of scientific licensing. Dr. Almenoff also led the development of pioneering systems for minimizing risk in drug development, which have been widely adopted by industry and regulators. Dr. Almenoff led or contributed to numerous regulatory submissions and product approvals. She is currently Chief Medical Officer of RedHill Biopharma (Nasdaq: RDHL). She also serves on the investment advisory board of the Harrington Discovery Institute and the boards of Brainstorm Cell Therapeutics (Nasdaq: BCLI) and inSoma Bio. Dr. Almenoff has strong expertise in translational medicine, clinical development, commercial strategy, and business development, and has previously advised biotech boards and management in these areas. Dr. Almenoff received her B.A. cum laude from Smith College and graduated with AOA honors from the M.D.-Ph.D. program at the Icahn (Mt. Sinai) School of Medicine. She completed post-graduate medical training at Stanford University Medical Center and served on the faculty of Duke University School of Medicine. She is an adjunct professor at Duke, a Fellow of the American College of Physicians (FACP) and has authored close to 60 publications.
- Rick D. Scruggs
Rick D. Scruggs，他曾一直担任业务发展执行副总裁（2011年1月以来）。他此前曾担任高级副总裁，负责业务拓展（从2009年1月到2011年1月）。他此前也曾担任副总裁，负责业务拓展（从2006年1月到2009年1月）。从2004年1月到2006年1月，他曾担任副总裁，负责商业发展。从2000年到2006年，他曾担任Salix公司的多种销售和商业贸易相关职务。加入Salix公司之前，他曾担任Watson公司的管理市场董事（从1997年5月到2000年7月）。此前，他曾担任Oclassen公司的董事，负责管理市场和贸易（从1995年1月到1997年2月）。加入Oclassen公司之前，他曾担任Johnson & Johnson公司和Ciba-Geigy公司的多种销售和营销职务，并不断被提拔。他持有Appalachian State University的刑事司法的学士学位。
Rick D. Scruggs has served as our Chief Commercial Officer since February 2020 and served as our Chief Operations Officer, U.S. Operations since January 1 2019 and as a member of our board of directors since January 1 2016. Mr. Scruggs most recently served as Executive Vice President of Business Development at Salix until its acquisition by Valeant now Bausch Health in March 2015. Mr. Scruggs joined Salix in 2000 after working at Oclassen Pharmaceuticals Inc. and Watson Pharmaceuticals, and helped build Salix’s commercial organization, serving in various sales and commercial trade-related positions. Mr. Scruggs was appointed as Executive Vice President in 2011 and was responsible for all business development activities as well as the worldwide distribution of Salix innovative products and intellectual property. Mr. Scruggs also served as the Head of the board of directors of Oceana Therapeutics, Salix’s European subsidiary. Mr. Scruggs holds a B.S. in Criminal Justice from the Appalachian State University in North Carolina.- Rick D. Scruggs，他曾一直担任业务发展执行副总裁（2011年1月以来）。他此前曾担任高级副总裁，负责业务拓展（从2009年1月到2011年1月）。他此前也曾担任副总裁，负责业务拓展（从2006年1月到2009年1月）。从2004年1月到2006年1月，他曾担任副总裁，负责商业发展。从2000年到2006年，他曾担任Salix公司的多种销售和商业贸易相关职务。加入Salix公司之前，他曾担任Watson公司的管理市场董事（从1997年5月到2000年7月）。此前，他曾担任Oclassen公司的董事，负责管理市场和贸易（从1995年1月到1997年2月）。加入Oclassen公司之前，他曾担任Johnson & Johnson公司和Ciba-Geigy公司的多种销售和营销职务，并不断被提拔。他持有Appalachian State University的刑事司法的学士学位。
- Rick D. Scruggs has served as our Chief Commercial Officer since February 2020 and served as our Chief Operations Officer, U.S. Operations since January 1 2019 and as a member of our board of directors since January 1 2016. Mr. Scruggs most recently served as Executive Vice President of Business Development at Salix until its acquisition by Valeant now Bausch Health in March 2015. Mr. Scruggs joined Salix in 2000 after working at Oclassen Pharmaceuticals Inc. and Watson Pharmaceuticals, and helped build Salix’s commercial organization, serving in various sales and commercial trade-related positions. Mr. Scruggs was appointed as Executive Vice President in 2011 and was responsible for all business development activities as well as the worldwide distribution of Salix innovative products and intellectual property. Mr. Scruggs also served as the Head of the board of directors of Oceana Therapeutics, Salix’s European subsidiary. Mr. Scruggs holds a B.S. in Criminal Justice from the Appalachian State University in North Carolina.
- Dror Ben Asher
Dror Ben Asher，2009年8月3日起，他担任我公司首席执行官和董事；2011年5月4日起，担任我公司董事会主席；2002年1月至2010年11月，担任P.C.M.I. Ltd.的经理，该公司是ProSeed Capital Holdings CVA的附属机构，为我公司提供咨询服务。他目前担任Agrea Ltd.的董事。他在英国莱斯特大学（University of Leicester）获得法学学士学位，在英国牛津大学（Oxford University）获得法学硕士学位，并在美国哈佛大学（Harvard University）完成了法学硕士学习。
Dror Ben Asher has served as our Chief Executive Officer and as a director since August 3 2009. Since May 4 2011 Mr. Ben-Asher has also served as Chairman of our board of directors. From January 2002 to November 2010 Mr. Ben-Asher served as a manager at P.C.M.I. Ltd., an affiliate of ProSeed Capital Holdings CVA. Mr. Ben-Asher holds an LLB from the University of Leicester, U.K., an MJur. from Oxford University, U.K. and completed LLM studies at Harvard University.- Dror Ben Asher，2009年8月3日起，他担任我公司首席执行官和董事；2011年5月4日起，担任我公司董事会主席；2002年1月至2010年11月，担任P.C.M.I. Ltd.的经理，该公司是ProSeed Capital Holdings CVA的附属机构，为我公司提供咨询服务。他目前担任Agrea Ltd.的董事。他在英国莱斯特大学（University of Leicester）获得法学学士学位，在英国牛津大学（Oxford University）获得法学硕士学位，并在美国哈佛大学（Harvard University）完成了法学硕士学习。
- Dror Ben Asher has served as our Chief Executive Officer and as a director since August 3 2009. Since May 4 2011 Mr. Ben-Asher has also served as Chairman of our board of directors. From January 2002 to November 2010 Mr. Ben-Asher served as a manager at P.C.M.I. Ltd., an affiliate of ProSeed Capital Holdings CVA. Mr. Ben-Asher holds an LLB from the University of Leicester, U.K., an MJur. from Oxford University, U.K. and completed LLM studies at Harvard University.
- Reza Fathi
Reza Fathi， 哲学博士。2010年5月1日起，他担任Redhill Biopharma Ltd.研发高级副总裁；2005至2009年，担任XTL Biopharmaceuticals Inc.的研究董事，XTL Biopharmaceuticals Inc.是生物技术公司，开发传染病小分子临床候选药物。2000至2005年，他担任Vivoquest, Inc.的研究董事， 负责利用组合技术开发治疗传染性疾病如丙肝和艾滋病的多个新颖产品。1998至2000年，他担任哈佛医学院（Harvard Medical School）化学协会和生物化学协会的生物化学研究经理，首创利用化学遗传学来辨认癌症化学中的小分子， 1991至1998年，主管PharmaGenics, Inc.的研发部门。他在纽约罗格斯大学（Rutgers University）获得化学博士学位并完成了博士后研究。
Reza Fathi, has served as Redhill Biopharma Ltd. Senior Vice President Research and Development since May 1 2010. From 2005 to 2009 Dr. Fathi served as a Director of Research in XTL Biopharmaceuticals Inc., a biotechnology company engaged in developing small molecule clinical candidates for infectious diseases. Prior to that, from 2000 to 2005 Dr. Fathi served as Director of Research at Vivoquest, Inc. where he was responsible for developing a number of novel natural product-based combinatorial technologies for infectious diseases such as HCV and HIV. Between 1998 to 2000 he served as a Manager of Chemical Biology Research at the Institute of Chemistry and Chemical Biology ICCB at Harvard Medical School, pioneering chemical genetics to identify small molecules in cancer biology, and from 1991 to 1998 headed the Discovery Group at PharmaGenics, Inc. Dr. Fathi holds a Postdoctoral and Ph.D. in Chemistry from Rutgers University.- Reza Fathi， 哲学博士。2010年5月1日起，他担任Redhill Biopharma Ltd.研发高级副总裁；2005至2009年，担任XTL Biopharmaceuticals Inc.的研究董事，XTL Biopharmaceuticals Inc.是生物技术公司，开发传染病小分子临床候选药物。2000至2005年，他担任Vivoquest, Inc.的研究董事， 负责利用组合技术开发治疗传染性疾病如丙肝和艾滋病的多个新颖产品。1998至2000年，他担任哈佛医学院（Harvard Medical School）化学协会和生物化学协会的生物化学研究经理，首创利用化学遗传学来辨认癌症化学中的小分子， 1991至1998年，主管PharmaGenics, Inc.的研发部门。他在纽约罗格斯大学（Rutgers University）获得化学博士学位并完成了博士后研究。
- Reza Fathi, has served as Redhill Biopharma Ltd. Senior Vice President Research and Development since May 1 2010. From 2005 to 2009 Dr. Fathi served as a Director of Research in XTL Biopharmaceuticals Inc., a biotechnology company engaged in developing small molecule clinical candidates for infectious diseases. Prior to that, from 2000 to 2005 Dr. Fathi served as Director of Research at Vivoquest, Inc. where he was responsible for developing a number of novel natural product-based combinatorial technologies for infectious diseases such as HCV and HIV. Between 1998 to 2000 he served as a Manager of Chemical Biology Research at the Institute of Chemistry and Chemical Biology ICCB at Harvard Medical School, pioneering chemical genetics to identify small molecules in cancer biology, and from 1991 to 1998 headed the Discovery Group at PharmaGenics, Inc. Dr. Fathi holds a Postdoctoral and Ph.D. in Chemistry from Rutgers University.
- Gilead Raday
Gilead Raday，2012年12月5日起，他担任我公司公司与产品发展高级副总裁 ；2010年11月至2012年12月，担任的公司与产品发展副总裁；2010年1月至2010年10月，担任肿瘤药物开发公司Sepal Pharma Plc。的临时首席执行官，2009年1月至2009年12月，担任独立顾问，负责生命科学领域的商业发展和项目管理；2004至2008年，担任投资银行Charles Street Securities Europe, LLP的合伙人，负责生命科学领域。他目前是Sepal Pharma Plc。和 ViDAC Limited的董事会成员。他曾担任Morria Biopharmaceuticals Plc.,Vaccine Research International Plc., TKsignal Plc。和Miras Medical Imaging Plc。的董事会成员。他在耶路撒冷希伯来大学（Hebrew University of Jerusalem）获得神经生物学硕士学位，在英国剑桥大学（Cambridge University）获得生物技术管理硕士学位。
Gilead Raday has served as our Chief Operating Officer since April 1 2016. From December 5 2012 until March 31 2016 Mr. Raday served as Senior Vice President Corporate and Product Development. From November 2010 to December 2012 Mr. Raday served as our Vice President Corporate and Product Development. From January 2010 until October 2010 Mr. Raday served as Interim Chief Executive Officer of Sepal Pharma Plc., an oncology drug development company, and from January 2009 to December 2009 he was an independent consultant, specializing in business development and project management in the field of life sciences. From 2004 to 2008 Mr. Raday was a partner in Charles Street Securities Europe, LLP, an investment banking firm, where he was responsible for the field of life sciences. Mr. Raday previously served on the boards of Sepal Pharma Plc., ViDAC Limited, Morria Biopharmaceuticals Plc., Vaccine Research International Plc., TKsignal Plc., and Miras Medical Imaging Plc. He received his M.Sc. in Neurobiology from the Hebrew University of Jerusalem, Israel, and an M.Phil. in Bioscience Enterprise from Cambridge University, U.K.- Gilead Raday，2012年12月5日起，他担任我公司公司与产品发展高级副总裁 ；2010年11月至2012年12月，担任的公司与产品发展副总裁；2010年1月至2010年10月，担任肿瘤药物开发公司Sepal Pharma Plc。的临时首席执行官，2009年1月至2009年12月，担任独立顾问，负责生命科学领域的商业发展和项目管理；2004至2008年，担任投资银行Charles Street Securities Europe, LLP的合伙人，负责生命科学领域。他目前是Sepal Pharma Plc。和 ViDAC Limited的董事会成员。他曾担任Morria Biopharmaceuticals Plc.,Vaccine Research International Plc., TKsignal Plc。和Miras Medical Imaging Plc。的董事会成员。他在耶路撒冷希伯来大学（Hebrew University of Jerusalem）获得神经生物学硕士学位，在英国剑桥大学（Cambridge University）获得生物技术管理硕士学位。
- Gilead Raday has served as our Chief Operating Officer since April 1 2016. From December 5 2012 until March 31 2016 Mr. Raday served as Senior Vice President Corporate and Product Development. From November 2010 to December 2012 Mr. Raday served as our Vice President Corporate and Product Development. From January 2010 until October 2010 Mr. Raday served as Interim Chief Executive Officer of Sepal Pharma Plc., an oncology drug development company, and from January 2009 to December 2009 he was an independent consultant, specializing in business development and project management in the field of life sciences. From 2004 to 2008 Mr. Raday was a partner in Charles Street Securities Europe, LLP, an investment banking firm, where he was responsible for the field of life sciences. Mr. Raday previously served on the boards of Sepal Pharma Plc., ViDAC Limited, Morria Biopharmaceuticals Plc., Vaccine Research International Plc., TKsignal Plc., and Miras Medical Imaging Plc. He received his M.Sc. in Neurobiology from the Hebrew University of Jerusalem, Israel, and an M.Phil. in Bioscience Enterprise from Cambridge University, U.K.
- Adi Frish
Adi Frish，2012年12月5日起，他担任我公司商业发展和发牌高级副总裁；2010年10月至2012年12月，担任商业发展和发牌副总裁；2006至2010年，担任内窥镜医疗设备公司，1998至2006年，担任律师事务所Y. Ben Dror & Co。的助理律师和合伙人。他在英国埃塞克斯大学（Essex University）获得法学学士学位，在以色列Bar-Ilan University 获得商业法学硕士学位。
Adi Frish has served as our Senior Vice President Business Development and Licensing since December 5 2012. From October 2010 to December 2012 Mr. Frish served as our Vice President Business Development and Licensing. From 2006 to 2010 Mr. Frish served as the Chief Business Development at Medigus Ltd., a medical device company in the endoscopic field, and from 1998 to 2006 Mr. Frish was an associate and a partner at the law firm of Y. Ben Dror & Co. Mr. Frish holds an LLB from Essex University, U.K. and an LLM in Business Law from the Bar-Ilan University, Israel.- Adi Frish，2012年12月5日起，他担任我公司商业发展和发牌高级副总裁；2010年10月至2012年12月，担任商业发展和发牌副总裁；2006至2010年，担任内窥镜医疗设备公司，1998至2006年，担任律师事务所Y. Ben Dror & Co。的助理律师和合伙人。他在英国埃塞克斯大学（Essex University）获得法学学士学位，在以色列Bar-Ilan University 获得商业法学硕士学位。
- Adi Frish has served as our Senior Vice President Business Development and Licensing since December 5 2012. From October 2010 to December 2012 Mr. Frish served as our Vice President Business Development and Licensing. From 2006 to 2010 Mr. Frish served as the Chief Business Development at Medigus Ltd., a medical device company in the endoscopic field, and from 1998 to 2006 Mr. Frish was an associate and a partner at the law firm of Y. Ben Dror & Co. Mr. Frish holds an LLB from Essex University, U.K. and an LLM in Business Law from the Bar-Ilan University, Israel.
- Guy Goldberg
Guy Goldberg，2012年7月16日起，他担任我公司首席商务官；2007年7月至2012年7月，担任Eagle Pharmaceuticals的副总裁，后担任商业运作高级副总裁， 该公司是位于新泽西的专业可注射药物开发公司；2004年至2007年，就职于医疗保健风险投资公司，2002至2004年，担任McKinsey & Company的顾问。他在耶鲁大学（Yale University）获得经济学和哲学学士学位，并在哈佛大学法学院（Harvard Law School）获得法学博士学位。
Guy Goldberg has served as our Chief Business Officer since 2012. From 2007 to 2012 Mr. Goldberg served as Vice President and then as Senior Vice President of Business Operations at Eagle Pharmaceuticals, a specialty injectable drug development company, based in New Jersey. From 2004 to 2007 Mr. Goldberg was an associate at ProQuest Investments, a healthcare-focused venture capital firm, and from 2002 to 2004 Mr. Goldberg was a consultant at McKinsey & Company. Mr. Goldberg holds a B.A. in Economics and Philosophy from Yale University and a J.D. from Harvard Law School.- Guy Goldberg，2012年7月16日起，他担任我公司首席商务官；2007年7月至2012年7月，担任Eagle Pharmaceuticals的副总裁，后担任商业运作高级副总裁， 该公司是位于新泽西的专业可注射药物开发公司；2004年至2007年，就职于医疗保健风险投资公司，2002至2004年，担任McKinsey & Company的顾问。他在耶鲁大学（Yale University）获得经济学和哲学学士学位，并在哈佛大学法学院（Harvard Law School）获得法学博士学位。
- Guy Goldberg has served as our Chief Business Officer since 2012. From 2007 to 2012 Mr. Goldberg served as Vice President and then as Senior Vice President of Business Operations at Eagle Pharmaceuticals, a specialty injectable drug development company, based in New Jersey. From 2004 to 2007 Mr. Goldberg was an associate at ProQuest Investments, a healthcare-focused venture capital firm, and from 2002 to 2004 Mr. Goldberg was a consultant at McKinsey & Company. Mr. Goldberg holds a B.A. in Economics and Philosophy from Yale University and a J.D. from Harvard Law School.